Managing multiple myeloma in the elderly: are we making progress?
about
Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis.Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling.50 Years ago in CORR: Multiple myeloma Warran A. Ross, MD CORR 1961;20:203-207.
P2860
Managing multiple myeloma in the elderly: are we making progress?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Managing multiple myeloma in the elderly: are we making progress?
@en
Managing multiple myeloma in the elderly: are we making progress?
@nl
type
label
Managing multiple myeloma in the elderly: are we making progress?
@en
Managing multiple myeloma in the elderly: are we making progress?
@nl
prefLabel
Managing multiple myeloma in the elderly: are we making progress?
@en
Managing multiple myeloma in the elderly: are we making progress?
@nl
P2093
P2860
P356
P1476
Managing multiple myeloma in the elderly: are we making progress?
@en
P2093
Andrew Spencer
H Miles Prince
Hang Quach
P2860
P304
P356
10.1586/EHM.11.18
P577
2011-06-01T00:00:00Z